Welcome to our dedicated page for Vivos SEC filings (Ticker: RDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivos Inc. (RDGL) SEC filings page on Stock Titan provides direct access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central for understanding how Vivos describes its radiotherapeutic business, regulatory strategy, leadership changes, and international expansion around its RadioGel® and IsoPet® platforms.
In current and historical Forms 8-K and 8-K/A, Vivos reports material events such as the appointment of senior executives, including a President and Chief Operating Officer, along with the key terms of their employment and consulting agreements. These filings outline responsibilities in business development, production, regulatory submissions, and intellectual property development for targeted cancer therapies that deliver radioactive agents directly to tumors while minimizing damage to healthy tissue.
Other 8-K filings document strategic decisions like the creation of Vivos Scientific India LLP, a wholly owned legal entity in India. Vivos states that this entity is intended to establish a manufacturing center, expand human therapies, pursue commercialization of therapies in India, and generate additional human trial data to support its process with the U.S. Food and Drug Administration. Such disclosures help investors follow how the company links international operations to its regulatory pathway.
By reviewing Vivos Inc.’s SEC filings, readers can see how the company formally communicates developments in governance, compensation, and strategic initiatives related to its radiotherapeutic technologies. On Stock Titan, these filings are updated from EDGAR in near real time, and AI-powered tools can help summarize key sections, highlight items such as executive appointments, and surface information relevant to topics like regulatory strategy, manufacturing plans, and corporate structure.
Vivos Inc reported an insider share purchase by its CEO and President, who is also a director. On 12/31/2025, the reporting person acquired 200,000 shares of common stock in an open-market purchase at a price of $0.0646 per share, as shown by transaction code "P" for a purchase. Following this transaction, the insider beneficially owns 10,935,090 common shares, held directly.
Vivos Inc. reported an insider share purchase by its CEO, President, and Director, Michael Korenko. On 12/02/2025, he bought 100,000 shares of Vivos Inc. common stock in an open-market transaction coded "P" at a price of $0.0722 per share. Following this transaction, he beneficially owns 10,735,090 shares of common stock in direct ownership.
Vivos Inc. (RDGL) reported an insider share purchase by its CEO and President, who is also a director. On 11/20/2025, the reporting person bought 100,000 shares of Vivos Inc. common stock in an open-market transaction coded "P" at a price of $0.0622 per share.
Following this transaction, the insider now beneficially owns 10,635,090 shares of Vivos Inc. common stock held directly.
Vivos Inc (RDGL) reported Q3 2025 results. For the nine months ended September 30, 2025, revenue was $43,627 versus $23,000 a year ago, while Q3 revenue was $1,879 versus $5,000. The company posted a nine‑month operating loss of $2,069,328 and a net loss of $1,987,503.
Cash was $2,202,109 as of September 30, 2025. Operating cash use totaled $1,518,189 for the period, partially offset by $1,507,750 from financing activities, including $1,506,250 raised via a Regulation A+ equity issuance and related warrants. Shares outstanding were 454,664,957 as of November 11, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and estimates it requires approximately $3.0 million annually to maintain operations and about $9.0 million over 36 months for clinical and commercialization plans. The Board approved Vivos Scientific India LLP on September 17, 2025, established October 1, 2025, to support manufacturing and human therapy initiatives.
Vivos Inc. filed an amended current report to correct typographical errors related to its description of a leadership appointment, while confirming two key executive changes. The company appointed Brad Allan Weeks as President under an employment agreement effective September 1, 2025 through December 31, 2027. His compensation includes an annual base salary of
David J. Swanberg was appointed Chief Operating Officer under an executive consulting agreement effective September 1, 2025 through December 31, 2028. He will receive consulting compensation of
Vivos Inc. appointed Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, effective September 1, 2025, with their appointments disclosed on September 15, 2025. Weeks previously served as the company’s Business Development Manager and has a background in medical devices and biotechnology, while Swanberg brings over 35 years of experience in radiochemical processing, medical isotope production, and nuclear technologies.
Under his employment agreement running through December 31, 2027, Weeks will receive a base salary of $192,000 per year plus a $3,000 monthly grant in common stock, issued at the end of each fiscal quarter based on the closing share price, along with customary benefits and expense reimbursement. Swanberg’s consulting agreement runs through December 31, 2028 and provides $12,000 per month in consulting fees plus a $3,000 monthly grant in common stock on the same quarterly pricing basis, with standard confidentiality, non‑competition, and non‑solicitation provisions for both executives.
Vivos Inc. reported that its Board of Directors approved the creation of Vivos Scientific India LLP, a wholly owned legal entity based in India. This new subsidiary is intended to establish a manufacturing center, expand the company’s human therapies, and pursue commercialization of those therapies in the Indian market.
The company also plans to use Vivos Scientific India to generate additional human clinical trial data to support its process with the U.S. Food and Drug Administration. This step reflects a strategic focus on both international expansion and building a stronger evidence base for regulatory review.